The investigational drug VT-1129 is a highly potent inhibitor of Cryptococcus species CYP51 but only weakly inhibits the human enzyme

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4530-4538

  Warrilow, Andrew G S ^a   Parker, Josie E ^a   Price, Claire L ^a   Nes, W David ^b   Garvey, Edward P ^c   Hoekstra, William J ^c   Schotzinger, Robert J ^c   Kelly, Diane E ^a   Kelly, Steven L ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b TEXAS TECH UNIVERSITY   (United States)

^c Viamet Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CLOTRIMAZOLE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; EBURICOL; ERGOSTA 7 ENOL; ERGOSTEROL; FLUCONAZOLE; FUNGAL ENZYME; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; MIDAZOLAM; OBTUSIFOLIONE; OMEPRAZOLE; STEROL 14ALPHA DEMETHYLASE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; TESTOSTERONE; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE; VT 1129; EBERICOL; PYRIDINE DERIVATIVE; VT-1129;

ANTIFUNGAL ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DNA SEQUENCE; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; FILOBASIDIELLA; HETEROLOGOUS EXPRESSION; HUMAN; IC50; IN VIVO STUDY; LIGAND BINDING; LIVER; NONHUMAN; PRIORITY JOURNAL; STEROL ANALYSIS; TURNOVER NUMBER; XENOBIOTIC METABOLISM; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM;

ANTIFUNGAL AGENTS; CLOTRIMAZOLE; CRYPTOCOCCUS; ENZYME ACTIVATION; ERGOSTEROL; FLUCONAZOLE; HUMANS; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; PYRIDINES; STEROL 14-DEMETHYLASE; TETRAZOLES; VORICONAZOLE;

EID: 84979518463     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00349-16     Document Type: Article

References (48)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530. http://dx.doi.org/10.1097/QAD.0b013e328322ffac.
2. Bicanic T, Harrison TS. 2004. Cryptococcal meningitis. Br Med Bull 72:99-118.
3. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, Alvarez M, Dellamonica P, Botterel F, Dromer F, Chene G, the French Cryptococcosis Study Group. 2006. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20: 2183-2191. http://dx.doi.org/10.1097/01.aids.0000252060.80704.68.
4. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. 2007. Determinants of disease presentation and outcome during cryptococcosis: the Crypto A/D study. PLoS Med 4:e21. http://dx.doi.org/10.1371/journal.pmed.0040021.
5. Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, Zumla A. 2001. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 77: 769-773. http://dx.doi.org/10.1136/pmj.77.914.769.
6. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, Lalloo D, Whitworth JAG, Gilks CF. 2002. Cryptococcal infection in a cohort of HIV-1-infected Ugandan aldults. AIDS 16:1031-1038. http://dx.doi.org/10.1097/00002030-200205030-00009.
7. Canteros CE, Brundy M, Rodero L, Perrotta D, Davel G. 2002. Distribution of Cryptococcus neoformans serotypes associated with human infections in Argentina. Rev Argent Microbiol 34:213-218. (In Spanish.)
8. Banerjee U, Datta K, Casadevall A. 2004. Serotype distribution of Cryptococcus neoformans in patients in a tertiary care center in India. Med Mycol 242:181-186.
9. Byrnes EJ, Bartlett KH, Perfect JR, Heitman J. 2011. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect 13:895-907. http://dx.doi.org/10.1016/j.micinf.2011.05.009.
10. Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionev E, Falk R, Parnmen S, Lumbsch HT, Boekhout T. 2015. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol 78:16-48. http://dx.doi.org/10.1016/j.fgb.2015.02.009.
11. Perfect JR, Cox GM. 1999. Drug resistance in Cryptococcus neoformans. Drug Resist Updat 2:259-269. http://dx.doi.org/10.1054/drup.1999.0090.
12. Rodero L, Mellado E, Rodriguez AC, Salve A, Guelfand L, Cahn P, Cuenca-Estrella M, Davel G, Rodriguez-Tudela JL. 2003. G484S amino acid substitution in lanosterol 14-α demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother 47:3653-3656. http://dx.doi.org/10.1128/AAC.47.11.3653-3656.2003.
13. Sionov E, Chang YC, Garraffo HM, Dolan MA, Ghannoum MA, Kwon-Chung KJ. 2012. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob Agents Chemother 56:1162-1169. http://dx.doi.org/10.1128/AAC.05502-11.
14. Sionov E, Lee H, Chang YC, Kwon-Chung KJ. 2010. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog 6:e1000848. http://dx.doi.org/10.1371/journal.ppat.1000848.
15. Hu G, Wang J, Choi J, Jung WH, Liu I, Litvintseva AP, Bicanic T, Aurora R, Mitchell TG, Perfect JR, Kronstad JW. 2011. Variation in chromosome copy number influences the virulence of Cryptococcus neoformans and occurs in isolates from AIDS patients. BMC Genomics 12: 526. http://dx.doi.org/10.1186/1471-2164-12-526.
16. Sheng C, Miao Z, Ji H, Yao J, Wang W, Che X, Dong G, Lu J, Guo W, Zhang W. 2009. Three-dimensional model of lanosterol 14α-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding. Antimicrob Agents Chemother 53:3487-3495. http://dx.doi.org/10.1128/AAC.01630-08.
17. Suzuki Y, Tokimatsu I, Sato Y, Kawasaki K, Sato Y, Goto T, Hashinaga K, Itoh H, Hiramatsu K, Kadota J. 2013. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin Chim Acta 424:119-122. http://dx.doi.org/10.1016/j.cca.2013.05.025.
18. Hoekstra WJ, Garvey EP, Moore WR, Rafferty SW, Yates CM, Schotzinger RJ. 2014. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett 24:3455-3458. http://dx.doi.org/10.1016/j.bmcl.2014.05.068.
19. Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF, Wiederhold NP. 2016. The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother 60: 2528-2531. http://dx.doi.org/10.1128/AAC.02770-15.
20. Barnes HJ, Arlotto MP, Waterman MR. 1991. Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli. Proc Natl Acad Sci U S A 88:5597-5601. http://dx.doi.org/10.1073/pnas.88.13.5597.
21. Warrilow AGS, Martel CM, Parker JE, Melo N, Lamb DC, Nes D, Kelly DE, Kelly SL. 2010. Azole binding properties of Candida albicans sterol 14-α demethylase (CaCYP51). Antimicrob Agents Chemother 54:4235-4245. http://dx.doi.org/10.1128/AAC.00587-10.
22. Arase M, Waterman MR, Kagawa N. 2006. Purification and characterization of bovine steroid 21-hydroxylase (P450c21) efficiently expressed in Escherichia coli. Biochem Biophys Res Commun 344:400-405. http://dx.doi.org/10.1016/j.bbrc.2006.03.067.
23. Bellamine A, Mangla AT, Nes WD, Waterman MR. 1999. Characterization and catalytic properties of the sterol 14α-demethylase from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 96:8937-8942. http://dx.doi.org/10.1073/pnas.96.16.8937.
24. Warrilow AGS, Parker JE, Kelly DE, Kelly SL. 2013. Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob Agents Chemother 57:1352-1360. http://dx.doi.org/10.1128/AAC.02067-12.
25. Estabrook RW, Peterson JA, Baron J, Hildebrandt AG. 1972. The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism, p 303-350. In Chignell CF (ed), Methods in pharmacology, vol 2. Appleton-Century-Crofts, New York, NY.
26. Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2379-2385.
27. Lamb DC, Kelly DE, Waterman MR, Stromstedt M, Rozman D, Kelly SL. 1999. Characteristics of the heterologously expressed human lanosterol 14α-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents. Yeast 15:755-763. http://dx.doi.org/10.1002/(SICI)1097-0061(19990630)15:9〈755::AID-YEA417〉3.0.CO;2-8.
28. Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JA, Nelson WL, Isoherranen N. 2009. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochem Pharmacol 77:258-268. http://dx.doi.org/10.1016/j.bcp.2008.10.012.
29. Morrison JF. 1969. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 185:269-286. http://dx.doi.org/10.1016/0005-2744(69)90420-3.
30. Copeland RA. 2005. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists, p 178-213. Wiley-Interscience, New York, NY.
31. Lepesheva GI, Ott RD, Hargrove TY, Kleshchenko YY, Schuster I, Nes WD, Hill GC, Villalta F, Waterman MR. 2007. Sterol 14α-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem Biol 14:1283-1293. http://dx.doi.org/10.1016/j.chembiol.2007.10.011.
32. Lepesheva GI, Zaitseva NG, Nes WD, Zhou W, Arase M, Liu J, Hill GC, Waterman MR. 2006. CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B= helix defines substrate preferences of sterol 14α-demethylase. J Biol Chem 281:3577-3585. http://dx.doi.org/10.1074/jbc.M510317200.
33. Parker JE, Warrilow AGS, Cools HJ, Fraaije BA, Lucas JA, Rigdova K, Griffiths WJ, Kelly DE, Kelly SL. 2013. Prothioconazole and prothioconazole-desthio activity against Candida albicans sterol 14α-demethylase (CaCYP51). Appl Environ Microbiol 79:1639-1645. http://dx.doi.org/10.1128/AEM.03246-12.
34. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24(28)-dien-3β,6α-diol. Biochem Biophys Res Commun 207:910-915. http://dx.doi.org/10.1006/bbrc.1995.1272.
35. Jefcoate CR. 1978. Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol 52:258-279. http://dx.doi.org/10.1016/S0076-6879(78)52029-6.
36. Parker JE, Warrilow AGS, Cools HJ, Martel CM, Nes WD, Fraaije BA, Lucas JA, Kelly DE, Kelly SL. 2011. Mechanism of binding of prothioconazole to Mycosphaerella graminicola CYP51 differs from that of other azole antifungals. Appl Environ Microbiol 77:1460-1465. http://dx.doi.org/10.1128/AEM.01332-10.
37. Lepesheva GI, Nes WD, Zhou W, Hill GC, Waterman MR. 2004. CYP51 from Trypanosoma brucei is obtusifoliol-specific. Biochemistry 43:10789-10799. http://dx.doi.org/10.1021/bi048967t.
38. Strushkevich N, Usanov SA, Park HW. 2010. Structural basis of human CYP51 inhibition by antifungal azoles. J Mol Biol 397:1067-1078. http://dx.doi.org/10.1016/j.jmb.2010.01.075.
39. Jefcoate CR, Gaylor JL, Calabrese RL. 1969. Ligand interactions with cytochrome P450. I. Binding of primary amines. Biochemistry 8:3455-3463.
40. Warrilow AGS, Melo N, Martel CM, Parker JE, Nes D, Kelly DE, Kelly SL. 2010. Expression, purification, and characterization of Aspergillus fumigatus sterol 14-α demethylase (CYP51) isoenzymes A and B. Antimicrob Agents Chemother 54:4225-4234. http://dx.doi.org/10.1128/AAC.00316-10.
41. Niwa T, Shiraga T, Takagi A. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28:1805-1808. http://dx.doi.org/10.1248/bpb.28.1805.
42. Zhang S, Pillai VC, Mada SR, Strom S, Venkataramanan R. 2012. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica 42: 409-416. http://dx.doi.org/10.3109/00498254.2011.631224.
43. Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. 2002. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30:314-318. http://dx.doi.org/10.1124/dmd.30.3.314.
44. Trilles L, Meyer W, Wanke B, Guarro J, Lazera M. 2012. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol 50:328-332. http://dx.doi.org/10.3109/13693786.2011.602126.
45. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY antimicrobial surveillance program (2009). Diagn Microbiol Infect Dis 69:45-50. http://dx.doi.org/10.1016/j.diagmicrobio.2010.08.013.
46. Bertout S, Drakulovski P, Kouanfack C, Krasteva D, Ngouana T, Dunyach-Remy C, Dongsta J, Aghokeng A, Delaporte E, Koulla-Shiro S, Reynes J, Mallie M. 2013. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients. Clin Microbiol Infect 19:763-769. http://dx.doi.org/10.1111/1469-0691.12019.
47. Lockhart SR, Iqbal N, Bolden CB, DeBess EE, Marsden-Haug N, Worhle R, Thakur R, Harris JR. 2012. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 73:144-148. http://dx.doi.org/10.1016/j.diagmicrobio.2012.02.018.
48. Vedula P, Smith K, Boulware DR, Meya DB, Garvey EP, Hoekstra WJ, Schotzinger RJ, Nielsen K. 2015. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs, poster F-763a. Abstr 55th Intersci Conf Antimicrob Agents Chemother, San Diego, CA. American Society for Microbiology, Washington, DC.